Table 3.
Biologic agent use in idiopathic and JIA uveitis
| Drug | Idiopathic Uveitis | JIA Uveitis |
|---|---|---|
| N = 92 (%) | N = 643 (%) | |
| TNF inhibitor | 49 (53) | 353 (55) |
| Adalimumab | 18 (20) | 196 (30) |
| Certolizumab | 0 (0) | 1 (0.2) |
| Etanercept | 0 (0) | 159 (25) |
| Golimumab | 1 (1) | 3 (0.5) |
| Infliximab | 36 (39) | 174 (27) |
| Abatacept | 0 (0) | 23 (4) |
| Anti-IL-1 | 0 (0) | 9 (1.5) |
| Anakinra | 0 (0) | 7 (0.2) |
| Rilonacept | 0 (0) | 1 (0.2) |
| Canakinumab | 0 (0) | 1 (0.2) |
| Rituximab | 0 (0) | 4 (0.5) |
| Tocilizumab | 0 (0) | 4 (0.5) |
Data in this table represent “ever drug use” in patients with data available on biologic drug exposure (92/92 patients with idiopathic uveitis and 643/646 patients with JIA uveitis)
JIA juvenile idiopathic arthritis